Biochemical Markers of Bone Metabolism and Paget s Disease of Bone

骨代谢和佩吉特骨病的生化标志物

• 批准号: G0801462/1
• 负责人: William Fraser
• 金额: $ 83.8万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0801462%2F1
• 关键词: Biochemical; Markers; Bone; Metabolism; Paget

Biochemical markers of bone metabolism are easily measured in either blood or urine samples. Identification of the best of these biomarkers that is able to detect bone disease,correlate with severity of disease and predict response to therapy in metabolic bone disease would be a major advantage to clinicians looking after patients with these diseases. The recently completed PRISM and the ongoing PRISM EZ study have provided a unique clinical data set in the largest population of patients with Paget s disease ever treated as part of a clinical trial. We will measure several new and established biochemical markers of bone metabolism in samples obtained from patients who completed the PRISM study and in those continuing within PRISM EZ and hope to identify which marker(s) best diagnose the condition, correlate with disease severity, predict a good response to treatment, failure of treatment, whether within the symptomatic treatment or intensive treatment arms of the trial patients can be identified by biomarkers that are non responders to treatment and whether these biomarkers correlate better than the currently used marker (ALP) with the clinical outcome. Identifying a biochemical marker(s) that predicts clinical outcome would help the early identification of patients who may respond to specific therapeutic approaches that may prevent unnecessary treatment and waste of valuable clinical resources.

骨代谢的生化标志物很容易在血液或尿液样本中测量。鉴定这些生物标志物中最好的，能够检测骨骼疾病，与疾病的严重程度相关，并预测对代谢性骨骼疾病治疗的反应，将是临床医生照顾这些疾病患者的主要优势。最近完成的PRISM和正在进行的PRISM EZ研究提供了最大的佩吉特病患者人群的独特临床数据集，作为临床试验的一部分。我们将测量从完成PRISM研究的患者和继续PRISM EZ研究的患者中获得的样本中的几种新的和已建立的骨代谢生化标志物，并希望确定哪些标志物最能诊断病情，与疾病严重程度相关，预测对治疗的良好反应，治疗失败，无论是在对症治疗还是强化治疗组中，都可以通过对治疗无应答的生物标志物以及这些生物标志物的相关性是否优于目前使用的标志物来识别患者（ALP）与临床结果。鉴定预测临床结果的生化标志物将有助于早期鉴定可能对特定治疗方法有反应的患者，这可以防止不必要的治疗和浪费宝贵的临床资源。